Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 4/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CA11 | O75493 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428390 | 1.00 | CDK5 (0.70) | CDK5CDK5R1PTGS2HTR1AHTR2A | |
| SCHEMBL13341165 | 1.00 | CDK5 (0.70) | CDK5CDK5R1PTGS2HTR1AHTR2A | |
| SCHEMBL3426282 | 0.90 | CDK5 (0.75) | CDK5CDK5R1PTGS2CA1CA2 | |
| SCHEMBL3426279 | 0.90 | CDK5 (0.75) | CDK5CDK5R1PTGS2CA1CA2 | |
| SCHEMBL13341169 | 0.90 | CDK5 (0.75) | CDK5CDK5R1PTGS2CA1CA2 | |
| SCHEMBL13341173 | 0.89 | CDK5 (0.86) | CDK5CDK5R1HTR1AHTR2AHTR7 | |
| SCHEMBL3426489 | 0.89 | CDK5 (0.86) | CDK5CDK5R1HTR1AHTR2AHTR7 | |
| SCHEMBL3426485 | 0.89 | CDK5 (0.86) | CDK5CDK5R1HTR1AHTR2AHTR7 | |
| SCHEMBL3426106 | 0.87 | CDK5 (0.55) | CDK5CDK5R1PTGS2HTR1AHTR2A | |
| SCHEMBL13341122 | 0.87 | CDK5 (0.55) | CDK5CDK5R1PTGS2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713958-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-05-11 | — | — | US | claimed |
| US-20090137555-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-28 | — | — | US | claimed |
| US-20050153955-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-14 | — | — | US | claimed |
| US-7713958-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-05-11 | — | — | US | disclosed |
| US-20090137555-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-7423031-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-09-09 | — | — | US | disclosed |
| US-20050153955-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153955-A1 | Compounds and compositions as protein kinase inhibitors | CDK1, CDK3, CDK11A | CDK5 16/4885CDK5R1 38/4885PTGS2 3936/4885 |
| US-20090137555-A1 | Compounds and Compositions as Protein Kinase Inhibitors | CDK1, CDK3, CDK2 | CDK5 14/4885CDK5R1 37/4885PTGS2 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.